This study shows that the prevalence of hypertension in subjects carrying a loss-of-function mutation in MC4R is less than that in overweight or obese control subjects. Metabolic measurements and results of a clinical trial testing an MC4R agonist suggest that melanocortinergic signaling influences blood pressure through an insulin-independent mechanism.